Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The corticostriatal and hippocampal circuits contribute to the neurobiological underpinnings of several neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease and schizophrenia. Based on biological function, these circuits can be clustered into motor circuits, associative/cognitive circuits and limbic circuits. Together, dysfunctions in these circuits produce the wide range of symptoms observed in related neuropsychiatric disorders. Intracellular signaling in these circuits is largely mediated through the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway with an additional role for the cyclic guanosine monophosphate (cGMP)/ protein kinase G (PKG) pathway, both of which can be regulated by phosphodiesterase inhibitors (PDE inhibitors). Through their effects on cAMP response element-binding protein (CREB) and Dopamine- and cAMP-Regulated PhosphoProtein MR 32 kDa (DARPP-32), cyclic nucleotide pathways are involved in synaptic transmission, neuron excitability, neuroplasticity and neuroprotection. In this clinical review, we provide an overview of the current clinical status, discuss the general mechanism of action of PDE inhibitors in relation to the corticostriatal and hippocampal circuits and consider several translational challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Are the Dorsal and Ventral Hippocampus Functionally Distinct Structures?
Fanselow, M. S., & Dong, H.-W. (2010) · Neuron · doi:10.1016/j.neuron.2009.11.031 · Cited by 3,358 · cited 1×
“The ventral part appears to be involved in limbic functions, motivated behavior, neuroendocrine functions and autonomic functions, thereby regulating the impact of emotional experiences and controlling general affective states (Fanselow and Dong, 2010).”
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763 · cited 1×
“D1 receptors activate the Gs/olf family of G proteins to stimulate cyclic adenosine monophosphate (cAMP) production and thereby the direct pathway in the striatum (Sibley et al., 1993; Beaulieu and Gainetdinov, 2011).”
Transcriptional regulation by the phosphorylation-dependent factor CREB
Mayr, B., & Montminy, M. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35085068 · Cited by 2,587 · cited 2×
“…postsynaptic strengthening, PKA can result in the activation of two subsequent pathways: the cAMP response element binding protein (CREB) pathway (Mayr and Montminy, 2001) and the Dopamine- and cAMP-Regulated PhosphoProtein MR 32 kDa (DARPP-32) pathway (Greengard, 2001; Svenningsson et al.,…”
Sex bias in neuroscience and biomedical research
Beery, A. K., & Zucker, I. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.07.002 · Cited by 1,763
Functional organization of the hippocampal longitudinal axis
Strange, B. A., Witter, M. P., Lein, E. S., & Moser, E. I. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3785 · Cited by 1,738 · cited 1×
“The hippocampus is also described as having a ventral and a dorsal part (in animals) or an anterior and a posterior part (in humans) with similar composition, but both supporting different functions (Strange et al., 2014).”
Surmeier, D. J., Ding, J., Day, M., Wang, Z., & Shen, W. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.008 · Cited by 1,203 · cited 1×
“Additionally, every circuit is modulated by dopamine (Surmeier et al., 2007; Surmeier et al., 2011).”
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652 · cited 1×
“As a result PDE1 inhibitors are investigated in clinical trials for their cognition enhancing potential in schizophrenic patients, as these patients are characterized (among others) by frontal dopaminergic hypofunction (Meyer-Lindenberg et al., 2002; Van Os and Kapur, 2009).”
DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling
Millar, J. K., Pickard, B. S., Mackie, S., James, R., Christie, S., Buchanan, S. R., Malloy, M. P., Chubb, J. E., Huston, E., Baillie, G. S., et al. (2005) · Science · doi:10.1126/science.1112915 · Cited by 648 · cited 2×
“The involvement of PDE4 in schizophrenia is also supported by interaction of PDE4B with Disrupted in schizophrenia 1 (DISC1) (Millar et al., 2005; Clapcote et al., 2007; Murdoch et al., 2007), which is a genetic susceptibility factor for schizophrenia (Chubb et al., 2008), and by the association of PDE4B polymorphisms…”
Impey, S., Mark, M., Villacres, E. C., Poser, S., Chavkin, C., & Storm, D. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80120-8 · Cited by 593 · cited 2×
“Targeting both cAMP and cGMP is hypothesized to be especially beneficial due to their function in both early and late consolidation (e.g., Impey et al., 1996; Lu et al., 1999).”
Sakamoto, K., Karelina, K., & Obrietan, K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07080.x · Cited by 543 · cited 1×
“After release, the protein BDNF binds to the tropomyosin-related kinase B (TrkB) receptor, which is the receptor with the highest affinity for BDNF, ultimately resulting in neuroprotection (Impey et al., 1996; Lu et al., 1999; Sakamoto et al., 2011; see Fig.”
The DISC locus in psychiatric illness
Chubb, J. E., Bradshaw, N. J., Soares, D. C., Porteous, D. J., & Millar, J. K. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002106 · Cited by 542
Behavioral phenotypes of Disc1 missense mutations in mice
Clapcote, S. J., Lipina, T. V., Millar, J. K., Mackie, S., Christie, S., Ogawa, F., Lerch, J. P., Trimble, K., Uchiyama, M., Sakuraba, Y., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.04.015 · Cited by 526
Chudasama, Y., & Robbins, T. W. (2006) · Biological Psychology · doi:10.1016/j.biopsycho.2006.01.005 · Cited by 484 · cited 1×
“Dysfunction of these circuits produces the wide range of motor, cognitive and affective symptoms observed in these neuropsychiatric disorders (Chudasama and Robbins, 2006).”
Rodent Models of Attention-Deficit/Hyperactivity Disorder
Sagvolden, T., Russell, V. A., Aase, H., Johansen, E. B., & Farshbaf, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.002 · Cited by 448 · cited 1×
“By increasing their release, PDE inhibitors affecting presynaptic cAMP pools are hypothesized to benefit disorders characterized by corticostriatal hypodopaminergia like ADHD and Parkinson’s disease (e.g. Okimura et al., 2015; Pliszka, 2005; Sagvolden et al., 2005; Arnsten and Pliszka, 2011).”
Myeku, N., Clelland, C. L., Emrani, S., Kukushkin, N. V., Yu, W. H., Goldberg, A. L., & Duff, K. E. (2016) · Nature Medicine · doi:10.1038/nm.4011 · Cited by 446
Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442 · cited 1×
“The latter was also reported in previous studies with the classic PDE4 inhibitor rolipram, yet it rescued decreased CREB activation (Gong et al., 2004; Comery et al., 2005).”
A role for synaptic plasticity in the adolescent development of executive function
Selemon, L. D. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.7 · Cited by 439 · cited 2×
“…hippocampus, these mechanisms also occur in brain structures of the corticostriatal circuits, like the striatum, frontal cortex and amygdala through cyclic nucleotide pathways (e.g. Calabresi et al., 1992; Lovinger and Tyler, 1996; Maren, 1996; Arnsten et al., 2005; Girault, 2012; Selemon, 2013).”
Arnsten, A. F. T., & Pliszka, S. R. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.020 · Cited by 383 · cited 1×
“By increasing their release, PDE inhibitors affecting presynaptic cAMP pools are hypothesized to benefit disorders characterized by corticostriatal hypodopaminergia like ADHD and Parkinson’s disease (e.g. Okimura et al., 2015; Pliszka, 2005; Sagvolden et al., 2005; Arnsten and Pliszka, 2011).”
Prefrontostriatal connections in relation to cortical architectonic organization in rhesus monkeys
Yeterian, E. H., & Pandya, D. N. (1991) · Journal of Comparative Neurology · doi:10.1002/cne.903120105 · Cited by 351
The neuropsychopharmacology of attention-deficit/hyperactivity disorder
Pliszka, S. R. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.026 · Cited by 276
Molecular neurobiology of dopaminergic receptors
Sibley, D. R., Monsma, F. J., & Shen, Y. (1993) · International review of neurobiology · doi:10.1016/s0074-7742(08)60573-5 · Cited by 255 · cited 1×
“D1 receptors activate the Gs/olf family of G proteins to stimulate cyclic adenosine monophosphate (cAMP) production and thereby the direct pathway in the striatum (Sibley et al., 1993; Beaulieu and Gainetdinov, 2011).”
The cholinergic system and hippocampal plasticity
Drever, B. D., Riedel, G., & Platt, B. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.037 · Cited by 240 · cited 1×
“The main modulatory projections to the hippocampus arise from the medial septal area (Cobb and Davies, 2005; Drever et al., 2011; TelesGrilo Ruivo and Mellor, 2013).”
Dysregulation of Protein Kinase A Signaling in the Aged Prefrontal Cortex
Ramos, B. P., Birnbaum, S. G., Lindenmayer, I., Newton, S. S., Duman, R. S., & Arnsten, A. F. T. (2003) · Neuron · doi:10.1016/s0896-6273(03)00694-9 · Cited by 218 · cited 1×
“Along this line, high doses of the PDE4 inhibitor rolipram impaired prefrontal cognitive function in aged, but not young monkeys, likely due to overstimulation of the already disinhibited cAMP/PKA signaling pathway in the aged prefrontal cortex (Ramos et al., 2003; Arnsten et al., 2005).”
Phototransduction: crystal clear
Ridge, K. D., Abdulaev, N. G., Sousa, M., & Palczewski, K. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00172-5 · Cited by 163 · cited 1×
“In contrast to other PDE families, the cGMP specific PDE6 family is restricted to retinal rod and cone cells and the pineal gland (Table 1; Miki et al., 1975; Morin et al., 2001; Ridge et al., 2003; Lakics et al., 2010).”
The Neurobiology of Dopamine Signaling
Greengard, P. (2001) · Bioscience Reports · doi:10.1023/a:1013205230142 · Cited by 133
Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease
Gurney, M. E., D'Amato, E. C., & Burgin, A. B. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0309-7 · Cited by 121 · cited 1×
“Increased PDE activity is assumed to reduce cyclic nucleotide signaling in pathways important for brain plasticity and neuroprotection and is therefore considered to be causal, while a decrease in PDE activity might be considered as compensatory (Bollen and Prickaerts, 2012; Gurney et al., 2015).”
The role of ventral striatal cAMP signaling in stress-induced behaviors
Plattner, F., Hayashi, K., Hernández, A., Benavides, D. R., Tassin, T. C., Tan, C., Day, J., Fina, M. W., Yuen, E. Y., Yan, Z., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4066 · Cited by 94 · cited 2×
“in disorders like depression, schizophrenia (negative symptoms) and anxiety disorders (Brink et al., 2008; Hebb et al., 2008; Schmidt et al., 2008; Zinn et al., 2009; Reierson et al., 2011; Smith et al., 2013; Ding et al., 2014; Rutter et al., 2014; Plattner et al., 2015; Zhang et al., 2015).”
Cited by
Dopamine and glutamate in schizophrenia: biology, symptoms and treatment
McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020) · World Psychiatry · doi:10.1002/wps.20693 · Cited by 612
Wang, H., Xu, J., Lazarovici, P., Quirion, R., & Zheng, W. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00255 · Cited by 436
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339
Wang, H., Zhang, F.-F., Xu, Y., Fu, H.-R., Wang, X.-D., Wang, L., Chen, W., Xu, X.-Y., Gao, Y.-F., Zhang, J.-G., et al. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa048 · Cited by 84
Metadata
- Authors
- Heckman, P. R. A., Blokland, A., Bollen, E. P. P., & Prickaerts, J.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 87
- Pages
- 233-254
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W2788944745
- Cited by
- 74
- References
- 29
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.